About the Company
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AIMT News
Aimmune Stock Halted as FDA Considers Peanut Allergy Treatment
Aimmune Therapeutics is hlated as the FDA conducts an efficacy meeting on the company's peanut allergy treatment candidate Palforzia. Aimmune Therapeutics is hlated as the FDA conducts an efficacy ...
Aimmune Therapeutics
This page shows the latest Aimmune Therapeutics news and features for those working in and with pharma, biotech and healthcare. Approval in the EU comes nine months after US authorisation. Aimmune ...
Nestle to Acquire Peanuts Allergic Treatment Maker Aimmune Therapeutics for $2 Billion; Target Price CHF 120
Five Things to Know in Crypto This Week: Coinbase and Ripple in SEC ViceSat, 30 Mar 2024 02:48:30 GMT Gold Is Ready For New Records As Central Banks Keep BuyingFri, 29 Mar 2024 19:16:37 GMT Key ...
NIMCO US, Inc.'s Net Worth
This is based on reported shares across multiple companies, which include Seres Therapeutics, Inc., Axcella Health Inc., and Aimmune Therapeutics, Inc.. Attention insiders: Dive deeper into market ...
Patrick G Enright's Net Worth
Who is Patrick G Enright? Patrick G Enright has an estimated net worth of $1.94 Billion. This is based on reported shares across multiple companies, which include VALENTIS INC, Inozyme Pharma, Inc ...
INKT MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Ovid Therapeutics Inc OVID
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Design Therapeutics Inc DSGN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Sage Therapeutics, Inc. (SAGE)
Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease.
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Loading the latest forecasts...